Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first‐line treatment within the randomized Phase <scp>III</scp> trial <scp>FIRE</scp> ‐3 ( <scp>AIO KRK</scp> ‐0306)